A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects
Status:
Active, not recruiting
Trial end date:
2021-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to compare the pharmacokinetics (PK), safety, tolerability and
immunogenicity of a single dose of 300 mg tralokinumab administered as a 1 × X mL
subcutaneous (SC) injection with Device A and 2 × Y mL consecutive SC injections with Device
B.